Currently there are no sufficiently validated biomarkers to aid the evaluation of new
tuberculosis vaccine candidates, the improvement of tuberculosis diagnostics or the …

Human infection with Mycobacterium tuberculosis can progress to active disease, be
contained as latent infection, or be eradicated by the host response. Tuberculosis …

Biomarkers are indispensable to the development of new tuberculosis therapeutics and
vaccines. The most robust biomarkers measure factors that are essential to the underlying …

Tuberculosis (TB) is an airborne infectious disease that kills almost two million individuals
every year. Multidrug‐resistant (MDR) TB is caused by strains of Mycobacterium …

New drugs, vaccines, and other therapies will be required to realise the goal of global
tuberculosis elimination or control. This Review covers the important role biomarkers can …

Tuberculosis (TB) is still responsible for the deaths of> 1 million people yearly worldwide,
and therefore its correct diagnosis is one of the key components of any TB eradication …

Evaluating therapy efficacy is crucial for patients with tuberculosis (TB), especially those with
drug-resistant tuberculosis (DR-TB). The World Health Organization currently recommends …

South Africa has the highest prevalence of HIV and tuberculosis (TB) co-infection globally.
Recurrent TB, caused by relapse or reinfection, makes up the majority of TB cases in South …

The challenge now is to validate the suggested biomarkers being described and then
reduce them to clinical practice. If this can be done, it offers the possibility of greatly …

Background. New, simple, and better-performing diagnostic tools are needed for the
diagnosis of tuberculosis (TB). Much effort has been invested in developing an antibody …